We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that it has entered into a definitive agreement to acquire privately held company, ReViral, for upto $525 million.
Pfizer is looking to boost its respiratory portfolio with ReViral’s novel antiviral therapeutics that target respiratory syncytial virus (“RSV”). The deal is likely to strengthen Pfizer’s capabilities in infectious disease research and help in developing a treatment for RSV infections and preventing illness through vaccination.
ReViral’s lead candidate, sisunatovir, an orally administered fusion inhibitor, is currently in mid-stage development for treating RSV infections in adults and infants. The candidate is being evaluated in a phase II study for treating RSV infections in hospitalized infants. The candidate has also significantly reduced viral load in a phase II RSV human challenge study in healthy adults.
ReViral also has a second program in a phase I study focused on the inhibition of RSV replication, targeting the viral N protein.
Pfizer believes that if successfully developed and upon potential approval, ReViral's RSV candidates have the potential to generate more than $1.5 billion in annual sales.
Shares of Pfizer have declined 6.6% so far this year against the industry’s increase of 7.4%.
Image Source: Zacks Investment Research
The acquisition of ReViral looks like a strategic fit for Pfizer as the company remains focused on addressing a significant unmet medical need for RSV treatments. The deal is likely to complement Pfizer’s ongoing RSV vaccine program. The transaction is subject to customary closing conditions.
Pfizer is already developing a RSV vaccine, PF-06928316, which is currently in late-stage studies for active immunization of pregnant women to prevent RSV-associated lower respiratory tract illness in infants from birth to up to six months of age.
PF-06928316 is also being studied to prevent lower respiratory tract disease caused by RSV in individuals aged 60 years and above.
Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank of #3 (Hold).
Better-ranked stocks in the healthcare sector include Innoviva, Inc. (INVA - Free Report) , Collegium Pharmaceutical, Inc. (COLL - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) . While Innoviva and Collegium Pharmaceutical sport a Zacks Rank #1 (Strong Buy), Voyager Therapeutics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Innoviva’s earnings has been revised 20.5% upward for 2022 and 27.9% upward for 2023 over the past 60 days. The INVA stock has rallied 13.8% year to date.
Earnings of Innoviva surpassed estimates in each of the trailing four quarters.
Collegium Pharmaceutical’s earnings estimates have been revised 50.6% upward for 2022 and 64.1% for 2023 over the past 60 days. The COLL stock has gained 10.5% year to date.
Earnings of Collegium Pharmaceutical surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 233.2% year to date.
Earnings of Voyager Therapeutics surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition
Pfizer Inc. (PFE - Free Report) announced that it has entered into a definitive agreement to acquire privately held company, ReViral, for upto $525 million.
Pfizer is looking to boost its respiratory portfolio with ReViral’s novel antiviral therapeutics that target respiratory syncytial virus (“RSV”). The deal is likely to strengthen Pfizer’s capabilities in infectious disease research and help in developing a treatment for RSV infections and preventing illness through vaccination.
ReViral’s lead candidate, sisunatovir, an orally administered fusion inhibitor, is currently in mid-stage development for treating RSV infections in adults and infants. The candidate is being evaluated in a phase II study for treating RSV infections in hospitalized infants. The candidate has also significantly reduced viral load in a phase II RSV human challenge study in healthy adults.
ReViral also has a second program in a phase I study focused on the inhibition of RSV replication, targeting the viral N protein.
Pfizer believes that if successfully developed and upon potential approval, ReViral's RSV candidates have the potential to generate more than $1.5 billion in annual sales.
Shares of Pfizer have declined 6.6% so far this year against the industry’s increase of 7.4%.
Image Source: Zacks Investment Research
The acquisition of ReViral looks like a strategic fit for Pfizer as the company remains focused on addressing a significant unmet medical need for RSV treatments. The deal is likely to complement Pfizer’s ongoing RSV vaccine program. The transaction is subject to customary closing conditions.
Pfizer is already developing a RSV vaccine, PF-06928316, which is currently in late-stage studies for active immunization of pregnant women to prevent RSV-associated lower respiratory tract illness in infants from birth to up to six months of age.
PF-06928316 is also being studied to prevent lower respiratory tract disease caused by RSV in individuals aged 60 years and above.
Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank of #3 (Hold).
Better-ranked stocks in the healthcare sector include Innoviva, Inc. (INVA - Free Report) , Collegium Pharmaceutical, Inc. (COLL - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) . While Innoviva and Collegium Pharmaceutical sport a Zacks Rank #1 (Strong Buy), Voyager Therapeutics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Innoviva’s earnings has been revised 20.5% upward for 2022 and 27.9% upward for 2023 over the past 60 days. The INVA stock has rallied 13.8% year to date.
Earnings of Innoviva surpassed estimates in each of the trailing four quarters.
Collegium Pharmaceutical’s earnings estimates have been revised 50.6% upward for 2022 and 64.1% for 2023 over the past 60 days. The COLL stock has gained 10.5% year to date.
Earnings of Collegium Pharmaceutical surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 233.2% year to date.
Earnings of Voyager Therapeutics surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.